國立虎尾科技大學 |

Monoclonal Antibodies in Headache = From Bench to Patient /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Monoclonal Antibodies in Headache / edited by Antoinette Maassen van den Brink, Paolo Martelletti.
Reminder of title:	From Bench to Patient /
other author:	Maassen van den Brink, Antoinette.
Description:	X, 172 p. 18 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Internal medicine. -
Online resource:	https://doi.org/10.1007/978-3-030-69032-8
ISBN:	9783030690328

Monoclonal Antibodies in Headache = From Bench to Patient /
Monoclonal Antibodies in Headache From Bench to Patient /[electronic resource] :edited by Antoinette Maassen van den Brink, Paolo Martelletti. - 1st ed. 2021. - X, 172 p. 18 illus. in color.online resource. - Headache,2197-6538. - Headache,.

The CGRP family of neuropeptides and their receptors in the trigeminovascular system.-Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.

Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.

ISBN: 9783030690328

Standard No.: 10.1007/978-3-030-69032-8doiSubjects--Topical Terms:

644638
Internal medicine.

LC Class. No.: RC1-1245

Dewey Class. No.: 616

Monoclonal Antibodies in Headache = From Bench to Patient /
LDR:02661nam a22004095i 4500 001 1053299
003 DE-He213
005 20210921182146.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030690328 $9 978-3-030-69032-8
024 7 $a 10.1007/978-3-030-69032-8 $2 doi
035 $a 978-3-030-69032-8
050 4 $a RC1-1245
072 7 $a MJ $2 bicssc
072 7 $a MED045000 $2 bisacsh
072 7 $a MJ $2 thema
082 0 4 $a 616 $2 23
245 1 0 $a Monoclonal Antibodies in Headache $h [electronic resource] : $b From Bench to Patient / $c edited by Antoinette Maassen van den Brink, Paolo Martelletti.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a X, 172 p. 18 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Headache, $x 2197-6538
505 0 $a The CGRP family of neuropeptides and their receptors in the trigeminovascular system.-Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications.
520 $a Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
650 0 $a Internal medicine. $3 644638
650 0 $a Neurology . $3 1253459
650 0 $a Psychopharmacology. $3 644799
650 1 4 $a Internal Medicine. $3 668583
650 2 4 $a Neurology. $3 593894
700 1 $a Maassen van den Brink, Antoinette. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1302032
700 1 $a Martelletti, Paolo. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 815755
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030690311
776 0 8 $i Printed edition: $z 9783030690335
776 0 8 $i Printed edition: $z 9783030690342
830 0 $a Headache, $x 2197-652X $3 1254719
856 4 0 $u https://doi.org/10.1007/978-3-030-69032-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)